As with other drugs, Tecfidera (dimethyl fumarate) can cause side effects, such as rash, nausea, or vomiting. If you’re not able to tolerate side effects of Tecfidera, talk with your doctor or ...

TECFIDERA (dimethyl fumarate) 120mg and 240mg delayed-release caps by Biogen Idec Biogen presented new data at ECTRIMS showing that Tecfidera (dimethyl fumarate) significantly reduced multiple ...

As Biogen’s relentless patent defense for blockbuster multiple sclerosis med Tecfidera came up short in the U.S., the company separately worked to fend off competition through an anticompetitive ...

(Reuters) - A U.S. federal appeals court on Wednesday upheld a ruling that Biogen Inc's patents on its blockbuster multiple sclerosis drug Tecfidera are valid, rejecting a challenge by Danish ...

Defending its blockbuster multiple sclerosis drug Tecfidera from generics hasn't been easy for Biogen lately, and the painful trend continued this week with a court ruling that clears the way for more ...

Tecfidera (dimethyl fumarate) is a prescription drug that’s used to treat certain types of multiple sclerosis. The drug comes as a delayed-release oral capsule. Tecfidera may not be safe to take while ...

Biogen has scored its first major success of the year, winning a patent challenge from Mylan over its multiple sclerosis drug Tecfidera. The challenge from Mylan focused on Biogen’s ‘514 patent on ...

WASHINGTONThe Food and Drug Administration said Wednesday it approved a new drug from Biogen Idec to control multiple sclerosis in adults with hard-to-treat forms of the disease. The twice-a-day ...

Tecfidera, Biogen Idec’s (BIIB) oral multiple sclerosis treatment, gained FDA approval recently for the first-line treatment of people with relapsing forms of multiple sclerosis. Biogen intends to ...

Warehoused patients, months of Wall Street hype, and positive clinical data all added to the anticipation around Biogen Idec’s Tecfidera MS drug. Months following launch, this Cinderella story—of a ...

Biogen CFO Paul Clancy told investors that a recently launched DTC campaign for multiple-sclerosis drug Tecfidera is showing “positive leading indicators,” including increased hits to the drug’s ...

On April 20, 2016, at the 68th annual meeting of the American Academy of Neurology (or AAN), Biogen presented data emphasizing the real-world efficacy of Tecfidera and highlighted the improved ...